LG Life Sciences eyes M&A with GeneSoft within this year

Published: 2003-11-18 07:00:00

Updated: 2003-11-18 07:00:00

LG Life Sciences might take its M&A bid to the US-based GeneSoft within this year to independently promote Factive in the global market due to the approval of additional indications, such as PRSP (Penicillin-resistant S. Pneumoniae) and MDRSP (multidrug- resistant Pneumoniae) from the US FDA, acc...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK